Adherence to CRC Screening and Surveillance Guidelines when Using Split-Dose Bowel Preparation

Table 2

Study participant characteristics by whether physician recommendation was guideline compliant or not ().

Patient characteristic	Compliant (; 86%)	Noncompliant (; 14%)	Total ()	value^a
Demographic characteristics
Age in years, mean (SD)	56.6 (6.6)	57.7 (8.2)	56.7 (6.8)	0.22
Male	196 (49.9)	33 (53.2)	229 (50.3)	0.62
White	340 (86.3)	54 (87.1)	394 (86.4)	0.86
Married	286 (72.6)	41 (66.1)	327 (71.7)	0.29
BMI^b, kg/m^2, mean (SD)	28.7 (5.7)	30.3 (6.0)	28.9 (5.7)	0.04
Full-time employment	232 (58.9)	31 (50.0)	263 (57.7)	0.19
On Medicaid or no insurance	16 (4.2)	3 (5.0)	19 (4.3)	0.76
≤75K annual income	153 (40.4)	29 (50.9)	182 (41.7)	0.13
Health-related measures
Very good or excellent health	264 (67.9)	35 (56.5)	299 (66.3)	0.08
History of stroke	10 (2.6)	2 (3.2)	12 (2.7)	0.67
On prescription pain pills	23 (5.9)	7 (11.3)	30 (6.6)	0.16
On tricyclic antidepressant^c	5 (1.3)	1 (1.6)	6 (1.3)	0.58
History of constipation	69 (17.8)	12 (19.4)	81 (18.0)	0.77

All values are N (% of split-dose compliant or % of split-dose noncompliant), unless otherwise specified. The total number of patients for each characteristic may not add to the total () due to missing data. ^aFrom testing differences in the distribution of the patient characteristics between patient compliant versus noncompliant to split-dose guideline, based on t-test for continuous variables and chi-square test or Fisher’s exact test for categorical variables. No adjustments for multiple testing were done as the tests were not meant to be inferential, but to identify variables that are potentially associated with guideline-compliant physician recommendation. ^bBody mass index ^con any of Tofranil, Elavil, Norpramin, Sinequan, and Pamelor.